Article ID Journal Published Year Pages File Type
9354894 Journal of Orthopaedic Science 2005 5 Pages PDF
Abstract
The results of the present study indicate that improved osseointegration of hydroxyapatite-coated and uncoated titanium implants is dose-dependent and requires high-dose application of bisphosphonate ibandronate equivalent to that needed to treat patients with tumor disease. Lower doses equivalent to those for treatment of osteoporosis showed no beneficial effect.
Related Topics
Health Sciences Medicine and Dentistry Orthopedics, Sports Medicine and Rehabilitation
Preview
High dosage treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants
Authors
, , ,